Qube Research & Technologies (QRT)’s MacroGenics MGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$542K Buy
+187,464
New +$400K ﹤0.01% 2714
2025
Q4
Sell
-22,415
Closed -$37.7K 3920
2025
Q3
$37.7K Buy
+22,415
New +$36.3K ﹤0.01% 3221
2024
Q2
Sell
-246,483
Closed -$3.63M 4388
2024
Q1
$3.63M Buy
246,483
+215,937
+707% +$3.26M 0.01% 1409
2023
Q4
$294K Buy
+30,546
New +$211K ﹤0.01% 2592
2022
Q3
Sell
-176,710
Closed -$521K 2813
2022
Q2
$521K Buy
176,710
+121,160
+218% +$637K ﹤0.01% 1390
2022
Q1
$489K Buy
55,550
+25,788
+87% +$285K ﹤0.01% 1538
2021
Q4
$478K Buy
29,762
+9,582
+47% +$180K ﹤0.01% 1597
2021
Q3
$423K Buy
+20,180
New +$486K 0.01% 1298

Other funds holding MGNX

Qube Research & Technologies (QRT)'s MGNX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) opened a new position in MacroGenics (MGNX) in Q1 2026: 187,464 shares worth $542K. The stake represents ﹤0.01% of the portfolio and ranks #2714 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in MGNX as recently as Q3 2025.

Qube Research & Technologies (QRT) first reported a position in MGNX in Q3 2021 and has held it in 8 quarters since. The position peaked at $3.63M in Q1 2024. 109 funds tracked by Wall St. Rank hold MGNX as of Q1 2026.

  • Qube Research & Technologies (QRT) held 187,464 shares of MacroGenics worth $542K as of Q1 2026.
  • MacroGenics was a new Qube Research & Technologies (QRT) position in Q1 2026.
  • MacroGenics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2714 holding.
  • Qube Research & Technologies (QRT) first reported a position in MacroGenics in Q3 2021 and has held it in 8 quarters since.
  • Qube Research & Technologies (QRT)'s MacroGenics position peaked at $3.63M in Q1 2024.
  • 109 funds tracked by Wall St. Rank held MacroGenics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.